The golden days for some drugs in China seem to be passing, and manufacturers are preparing to battle sizzling competition by raising cash and focusing more on profitable innovative therapies as demand for such products rises.
US giant Eli Lilly & Co. has seemingly become the latest multinational pharma firm to decide to divest maturing...